drugset / Trial / NCT02228707

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

NCT02228707

Phase 1 Completed 56 enrolled Biogen
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objectives of the study are to evaluate the safety and tolerability of multiple doses of BIIB061 administered to healthy adults. The secondary objective is to determine the multiple-dose PK profile of BIIB061 in this study population.

Timeline

Start
2014-08
Primary completion
2016-05
Completion
2016-05

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB061 Unknown

Indications

No indication recorded.